RDY:NYSE
Dr Reddy's Laboratories Ltd
13,07Â US$
arrow_upward
+1,32%(+0,17) 1D
13,07Â US$
0,00% (0,00)
bedtimeJashtë orarit
Mbyllur: 16 tet, 4:00:07 m.d., GMT-4 · USD
search
TĂ« gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për RDY...
Hap
13,00Â US$
I lartë
13,07Â US$
I ulët
12,94Â US$
Kapitalizimi i tregut
10,81Â mld
VĂ«llimi mesatar
3,19Â mln
VĂ«llimi
2,79Â mln
Dividendi
0,64%
Dividendi tremujor
0,02Â US$
Data e ndërprerjes së dividendit
10 korr 2026
Raporti çmim/fitim
31,34
Maksimumi 52-javor
15,67Â US$
Minimumi 52-javor
11,36Â US$
Fitimet për aksion
0,42Â US$
Beta
0,30
Aksionet në qarkullim
834,64Â mln
Numri i punonjësve
28 mijë
Hap
13,00Â US$
I lartë
13,07Â US$
I ulët
12,94Â US$
Kapitalizimi i tregut
10,81Â mld
VĂ«llimi mesatar
3,19Â mln
VĂ«llimi
2,79Â mln
Dividendi
0,64%
Dividendi tremujor
0,02Â US$
Data e ndërprerjes së dividendit
10 korr 2026
Raporti çmim/fitim
31,34
Maksimumi 52-javor
15,67Â US$
Minimumi 52-javor
11,36Â US$
Fitimet për aksion
0,42Â US$
Beta
0,30
Aksionet në qarkullim
834,64Â mln
Numri i punonjësve
28 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
MarketBeat
·
1 ditë më parë
Dr. Reddy's Laboratories (NYSE:RDY) Stock Rating Raised to "Hold" at Wall Street Zen
ad-hoc-news.de
·
2 ditë më parë
Dr Reddy reports three FDA observations: what it means for Dr Reddy stock
Profili
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Rreth Dr Reddy's Laboratories Ltd
Drejtori ekzekutivErez Israeli
Punonjësit27,5 mijë
Themeluar më1984
SeliaHiderabad, Andra Pradesh, Indi
Sektori-
Uebsajtidrreddys.com